Medicare decided to run the program themselves instead of waiting for insurers to cooperate.
In a quiet but consequential pivot, Medicare has chosen to dispense GLP-1 weight-loss medications directly to older Americans rather than compel a reluctant insurance industry to carry them. Beginning July 2026, seniors will access drugs like Wegovy and Zepbound through a temporary bridge program at a $50 monthly copay, after major insurers CVS Health and UnitedHealth declined to join the original mandatory framework. The arrangement is provisional, running only through 2027, yet it reflects a recurring tension in American healthcare: the distance between policy ambition and the operational willingness of private markets to serve public ends.
- The original BALANCE program collapsed at its own deadline when the two largest U.S. insurers refused to commit, leaving Medicare without a viable path through the private market.
- Rather than stall, Medicare officials improvised a parallel distribution system that routes GLP-1 drugs directly to enrollees, bypassing the standard Part D prescription benefit entirely.
- Drugmakers Eli Lilly and Novo Nordisk quickly endorsed the bridge arrangement, securing guaranteed access and negotiated pricing even within a structure neither company designed.
- The $50 monthly copay remains unchanged from the original plan, offering seniors continuity of cost even as the delivery mechanism shifts beneath them.
- The Medicaid side of BALANCE moves forward separately, with states given until July 31 to apply — preserving at least part of the original vision at the state level.
- Analysts warn the bridge buys time but not answers: what Medicare does with obesity coverage after 2027 remains an open and politically loaded question.
Medicare has abandoned its effort to mandate insurance coverage for GLP-1 weight-loss drugs and will instead distribute them directly to enrollees, starting July 1, 2026. The shift follows the collapse of the BALANCE program, which required insurers to participate by an April 20 deadline — a commitment that CVS Health and UnitedHealth both declined to make, citing operational complexity and unresolved uncertainty.
Under the new bridge arrangement, Medicare enrollees aged 65 and older can access medications like Wegovy and Zepbound at prices negotiated directly with manufacturers Eli Lilly and Novo Nordisk. The monthly copay holds at $50, matching what the original insurance-based plan would have charged. The drugs will flow through a parallel channel outside the standard Part D structure, effectively cutting insurers out of the equation for now.
Both pharmaceutical companies expressed support for the interim program. Lilly, which also makes the newer oral drug Foundayo, reaffirmed its commitment to the longer-term BALANCE vision while backing the bridge. Novo Nordisk did the same. The Medicaid component of BALANCE continues on a separate track, with states invited to apply for a jointly funded program by July 31.
The bridge runs only through the end of 2027, leaving the question of permanent Medicare obesity coverage unresolved. Analysts at J.P. Morgan have noted that once a benefit like this takes hold, political momentum tends to make it difficult to dismantle. For now, the weight-loss drug market — and millions of older Americans — are watching to see whether a temporary fix quietly becomes the new foundation.
Medicare is taking a different path to get weight-loss drugs into the hands of older Americans. Rather than forcing insurance companies to cover medications like Wegovy and Zepbound, the federal health program will dispense them directly, starting July 1, 2026, through a temporary arrangement that sidesteps the traditional insurance system altogether.
The shift came after major insurers balked at a mandatory program announced late last year. CVS Health, which owns Aetna, declined to participate. UnitedHealth cited unresolved operational questions and what it called "notable challenges" with the original plan. With the April 20 deadline for insurers to commit having passed, Medicare officials decided to move forward on their own terms instead of waiting for the private insurance market to cooperate.
Under the bridge program, which will run through the end of 2027, Medicare enrollees aged 65 and older will be able to access GLP-1 medications at prices negotiated directly with manufacturers Eli Lilly and Novo Nordisk. The monthly copay is set at $50, the same amount that would have been charged under the original insurance-based approach. The medications will be distributed outside the standard Medicare Part D prescription drug benefit structure, creating a parallel system that bypasses the usual insurance intermediaries.
The original plan, called BALANCE—an acronym for Better Approaches to Lifestyle and Nutrition for Comprehensive Health—was positioned as a way to expand access to obesity treatments while keeping costs off the federal budget. When it was announced at the end of 2025, Medicare Administrator Mehmet Oz framed it as a solution that would "expand access and lower prices for obesity GLP-1 medications without passing the bill to taxpayers." But insurers saw operational hurdles that made them hesitant to sign on, and the deadline passed with insufficient buy-in.
Lilly, which manufactures both Zepbound and the newer pill Foundayo, expressed support for the bridge program while maintaining its commitment to the longer-term BALANCE vision. Novo Nordisk similarly endorsed the interim arrangement. Both companies stand to benefit from the guaranteed access and negotiated pricing, even if the structure is temporary.
The Medicaid portion of BALANCE will continue moving forward. States have until July 31, 2026, to apply to participate in a program jointly funded by federal and state governments, giving them more direct control over implementation than Medicare insurers have.
What happens after 2027 remains uncertain. Analysts note that the bridge program buys time and reduces near-term pressure on demand, but it leaves the question of permanent Medicare integration unresolved. J.P. Morgan's Chris Schott suggested that once obesity treatment becomes an established benefit, political and practical realities will make it difficult to reverse course. The weight-loss drug market is watching closely to see whether this temporary fix becomes the foundation for something more durable.
Citações Notáveis
Expand access and lower prices for obesity GLP-1 medications without passing the bill to taxpayers.— Medicare Administrator Mehmet Oz, describing the original BALANCE program
Once this obesity benefit is established, it will be practically and politically difficult to roll back as we look toward 2028 and beyond.— J.P. Morgan analyst Chris Schott
A Conversa do Hearth Outra perspectiva sobre a história
Why did Medicare need to step in directly instead of just requiring insurers to cover these drugs?
The insurers said they had too many unanswered questions about how to implement it. CVS and UnitedHealth both said no, and without their participation, the whole mandatory system fell apart. Medicare decided it was faster to just run the program themselves.
So the patient experience is the same—$50 a month—but the money flows differently?
Exactly. The copay is identical. But instead of going through your insurance company's pharmacy network, Medicare is handling the distribution directly. It's a workaround, not a solution.
Is this permanent?
No. It's a bridge through the end of 2027. After that, nobody really knows. The companies say they want the long-term BALANCE program to work, but there's no guarantee it will.
What about Medicaid?
That's still moving forward as planned. States can opt in through July. Medicaid has more flexibility because states run their own programs, so there's less coordination required.
Why would analysts think this becomes politically hard to reverse?
Once millions of seniors are getting these drugs and seeing results, taking that benefit away becomes a third-rail issue. It's easier to expand a program than to cut one people depend on.
So this buys time for what, exactly?
For figuring out how to make the permanent system work. For the drug companies to prove demand. For everyone to see if the model actually functions at scale.